Current Progress in CAR-T Cell Therapy for Solid Tumors

Cancer immunotherapy by chimeric antigen receptor-modified T (CAR-T) cells has shown exhilarative clinical efficacy for hematological malignancies. Recently two CAR-T cell based therapeutics, Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) approved by US FDA (US Food and Drug Admin...

Full description

Saved in:
Bibliographic Details
Published in:International journal of biological sciences 2019-01, Vol.15 (12), p.2548-2560
Main Authors: Ma, Shuo, Li, Xinchun, Wang, Xinyue, Cheng, Liang, Li, Zhong, Zhang, Changzheng, Ye, Zhenlong, Qian, Qijun
Format: Article
Language:English
Subjects:
Acute lymphoblastic leukemia
Antigens
Apoptosis
B-cell lymphoma
Brain cancer
Brain research
Breast cancer
Cancer immunotherapy
Cancer therapies
Cell therapy
Chimeric antigen receptors
Clinical trials
Colorectal cancer
Cytokines
Gastric cancer
Hematology
Immunotherapy
Leukemia
Liver cancer
Lung cancer
Lymphatic leukemia
Lymphocytes
Lymphocytes B
Lymphocytes T
Lymphoma
Metastasis
Neuroblastoma
Ovarian cancer
Pancreatic cancer
Prostate
Regulatory agencies
Research centers
Review
Solid tumors
Therapy
Tumor microenvironment
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer immunotherapy by chimeric antigen receptor-modified T (CAR-T) cells has shown exhilarative clinical efficacy for hematological malignancies. Recently two CAR-T cell based therapeutics, Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) approved by US FDA (US Food and Drug Administration) are now used for treatment of B cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) respectively in the US. Despite the progresses made in treating hematological malignancies, challenges still remain for use of CAR-T cell therapy to treat solid tumors. In this landscape, most studies have primarily focused on improving CAR-T cells and overcoming the unfavorable effects of tumor microenvironment on solid tumors. To further understand the current status and trend for developing CAR-T cell based therapies for various solid tumors, this review emphasizes on CAR-T techniques, current obstacles, and strategies for application, as well as necessary companion diagnostics for treatment of solid tumors with CAR-T cells.
ISSN:1449-2288
1449-2288
DOI:10.7150/ijbs.34213